Cargando…

Potential mechanisms of resistance to current anti-thrombotic strategies in Multiple Myeloma

Multiple Myeloma (MM) is a common haematological malignancy that is associated with a high rate of venous thromboembolism (VTE) with almost 10% of patients suffering thrombosis during their disease course. Recent studies have shown that, despite current thromboprophylaxis strategies, VTE rates in MM...

Descripción completa

Detalles Bibliográficos
Autores principales:	Comerford, Claire, Glavey, Siobhan, O’Sullivan, Jamie M., Quinn, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	OAE Publishing Inc. 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992590/ https://www.ncbi.nlm.nih.gov/pubmed/35582539 http://dx.doi.org/10.20517/cdr.2021.115

Ejemplares similares

The role of VWF/FVIII in thrombosis and cancer progression in multiple myeloma and other hematological malignancies
por: Comerford, Claire, et al.
Publicado: (2022)

Induction Treatment in Transplant-eligible Multiple Myeloma
por: Quinn, J., et al.
Publicado: (2021)

Genetic Abnormalities in Extramedullary Multiple Myeloma
por: McAvera, Roisin, et al.
Publicado: (2023)

Bispecific Antibodies in Multiple Myeloma: Opportunities to Enhance Efficacy and Improve Safety
por: Swan, Dawn, et al.
Publicado: (2023)

Gene expression profiling as a prognostic tool in multiple myeloma
por: Black, Harmony, et al.
Publicado: (2021)

PB1996: TREATMENT PATHWAYS AT FIRST RELAPSE POST-ASCT IN MULTIPLE MYELOMA: IMPACT OF MAINTENANCE THERAPY ON TREATMENT OPTIONS
por: Duane, C., et al.
Publicado: (2022)

Laboratory features of tumour lysis syndrome following daratumumab monotherapy in relapsed/refractory multiple myeloma
por: Shackleton, Louisa, et al.
Publicado: (2020)

Validation of Risk-Adapted Venous Thromboembolism Prediction in Multiple Myeloma Patients
por: Barrett, Aisling, et al.
Publicado: (2021)

Emergence of chronic myeloid leukemia following autologous stem cell transplantation in a young woman with multiple myeloma
por: Barrett, Aisling, et al.
Publicado: (2018)

Adoptive Immunotherapy and High-Risk Myeloma
por: Duane, Catherine, et al.
Publicado: (2023)

Lenalidomide in Multiple Myeloma: Review of Resistance Mechanisms, Current Treatment Strategies and Future Perspectives
por: Kulig, Piotr, et al.
Publicado: (2023)

Global Epigenetic Regulation of MicroRNAs in Multiple Myeloma
por: Zhang, Wenjing, et al.
Publicado: (2014)

Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma
por: Saltarella, Ilaria, et al.
Publicado: (2020)

CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies
por: Zhang, Xiaomin, et al.
Publicado: (2023)

Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective
por: Ludwig, Heinz, et al.
Publicado: (2010)

Thrombotic microangiopathy associated with bortezomib treatment in a patient with relapsed multiple myeloma
por: Salmenniemi, Urpu, et al.
Publicado: (2012)

Combined Coagulopathy Can Induce Both Hemorrhagic and Thrombotic Complications in Multiple Myeloma
por: Kawashima, Ichiro, et al.
Publicado: (2018)

Renal Thrombotic Microangiopathy Associated with the Use of Bortezomib in a Patient with Multiple Myeloma
por: Van Keer, Jan, et al.
Publicado: (2016)

Approach to Contemporary Risk Assessment, Prevention and Management of Thrombotic Complications in Multiple Myeloma
por: Fotiou, Despina, et al.
Publicado: (2022)

Bortezomib-induced hyponatremia: tolvaptan therapy permits continuation of lenalidomide, bortezomib and dexamethasone therapy in relapsed myeloma
por: O’Connor-Byrne, N., et al.
Publicado: (2019)

Molecular mechanisms in multiple myeloma drug resistance
por: Nikesitch, Nicholas, et al.
Publicado: (2016)

Innovative Anti-CD38 and Anti-BCMA Targeted Therapies in Multiple Myeloma: Mechanisms of Action and Resistance
por: De Novellis, Danilo, et al.
Publicado: (2022)

Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update
por: Nijhof, Inger S., et al.
Publicado: (2017)

Stem cell mobilization in multiple myeloma: challenges, strategies, and current developments
por: Wei, Xiaolei, et al.
Publicado: (2023)

Biological Background of Resistance to Current Standards of Care in Multiple Myeloma
por: Mogollón, Pedro, et al.
Publicado: (2019)

Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma
por: Hobeika, Liliane, et al.
Publicado: (2014)

Drug-induced Thrombotic Microangiopathy During Maintenance Treatment in a Patient With Multiple Myeloma
por: Higuero Saavedra, Víctor, et al.
Publicado: (2019)

Two cases of carfilzomib‐induced thrombotic microangiopathy successfully treated with Eculizumab in multiple myeloma
por: Rassner, Michael, et al.
Publicado: (2021)

Mutations in the alternative complement pathway in multiple myeloma patients with carfilzomib-induced thrombotic microangiopathy
por: Moscvin, Maria, et al.
Publicado: (2023)

Understanding the Mechanisms of Resistance to T Cell-based Immunotherapies to Develop More Favorable Strategies in Multiple Myeloma
por: Ahn, Sungwoo, et al.
Publicado: (2021)

Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma
por: Issa, Mark E., et al.
Publicado: (2017)

Emerging Therapeutic Strategies to Overcome Drug Resistance in Multiple Myeloma
por: Davis, Lorraine N., et al.
Publicado: (2021)

The LIN28B/let-7 axis is a novel therapeutic pathway in Multiple Myeloma
por: Manier, Salomon, et al.
Publicado: (2016)

Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma
por: Yang, Wen-Chi, et al.
Publicado: (2015)

Appropriate Anti-Thrombotic/Anti-Thrombin Therapy for Thrombotic Lesions
por: Iqbal, Zafar, et al.
Publicado: (2012)

Autophagy and Apoptosis: Current Challenges of Treatment and Drug Resistance in Multiple Myeloma
por: Al-Odat, Omar S., et al.
Publicado: (2022)

Anti-thrombotic strategies in patients with atrial fibrillation undergoing PCI
por: Schäfer, Andreas, et al.
Publicado: (2020)

Red blood cells from COVID-19 patients suffer from increased oxidative stress and may have increased lactate influx
por: Mullen, Edel, et al.
Publicado: (2022)

Multiple myeloma current treatment algorithms
por: Rajkumar, S. Vincent, et al.
Publicado: (2020)

Current and Novel Alkylators in Multiple Myeloma
por: Schjesvold, Fredrik, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hapt1o0ctdpqjapk3bk9i7isci